Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.
about
Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapiesAn update on enzalutamide in the treatment of prostate cancerEnzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer.Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone.Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide.The evolution of prostate cancer therapy: targeting the androgen receptorEnzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancerNovel agents for castration-resistant prostate cancer: Early experience and beyond.What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature.Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents.The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer.Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review.Recent advances in circulating tumor cells and cell-free DNA in metastatic prostate cancer: a review.Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions.Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia.Current treatment strategies for advanced prostate cancer.
P2860
Q27011642-260F38E9-9537-4E2E-94BD-D4E834884760Q28087106-5FEEB36E-7179-4E0B-BB8D-2BCEE9C1D02AQ34464312-372C8366-BC88-4FD5-ABF1-399035CE80E8Q34484835-8BA04D7C-74D3-4449-BB8A-27ED357D835FQ36167019-FB38F826-D758-422E-9BCE-AB43F37F7EC9Q36823062-D2B8540D-1B86-433F-A94B-BEBB9ACB7E7AQ37257453-4C63D143-1931-4128-A1B6-A741265F3233Q37496652-64E4F6D2-5102-448A-B671-B886218A6DC3Q38232184-FF98E157-25B6-4A8F-973B-64E843F5C87BQ38241095-DBA186A1-8987-42AF-A8EB-C045128A7343Q38266909-1D7F3B29-065B-4865-8D4F-261C44E700C8Q38276818-EA6BCFB7-255C-4405-86A2-25FF1D4A65C9Q38574684-7C0345A3-3EA8-4C11-AFC1-96F9A2D4BEF5Q38587547-94785E4E-099E-462A-89EA-33D5C90D3B6AQ38678110-C72E0B1A-BB3A-42FD-AFCC-7B128D3F93CAQ38730792-82F628B1-4BC8-4FF6-968D-B5365B2B504EQ38731861-6B659F0C-364F-4A0E-A269-CA0569BA7F38Q38841082-33FAF59C-453B-4B1C-B4DB-0DD939AE388AQ38841385-E122E1B2-FE2D-4A49-BEE1-0B772C9EF0E5Q39454057-A0C4E8D3-0647-4062-9FC4-6F8B9839F48BQ41339007-B9E90636-33C4-4ADC-B592-FDDBC55726E7Q41561381-48EA441F-5DEE-4170-90BF-BC1786443AC9Q42575268-BD288808-8D91-4178-A543-7B36FC13AE85Q42934135-DBC1BC6A-4E96-410D-B4A8-0969FE9B2E95Q48561494-843E4932-A400-4DCA-9247-47B43F87DC6D
P2860
Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Enzalutamide treatment in pati ...... erapy and abiraterone acetate.
@en
Enzalutamide treatment in pati ...... erapy and abiraterone acetate.
@nl
type
label
Enzalutamide treatment in pati ...... erapy and abiraterone acetate.
@en
Enzalutamide treatment in pati ...... erapy and abiraterone acetate.
@nl
prefLabel
Enzalutamide treatment in pati ...... erapy and abiraterone acetate.
@en
Enzalutamide treatment in pati ...... erapy and abiraterone acetate.
@nl
P2093
P1476
Enzalutamide treatment in pati ...... herapy and abiraterone acetate
@en
P2093
Frederik Birkebaek Thomsen
Klaus Brasso
Michael Borre
Per Rathenborg
Peter Iversen
P304
P356
10.3109/21681805.2013.860189
P577
2013-11-21T00:00:00Z